GE HealthCare to acquire IMACTIS, CT navigation designer for interventional radiology
por John R. Fischer, Senior Reporter | January 10, 2023
Business Affairs
CT
Operating Room
X-Ray
GE HealthCare has acquired IMACTIS, designer of the CT-Navigation platform.
GE HealthCare has announced its first official acquisition agreement as an independent company, with plans to acquire French manufacturer IMACTIS, designer of the CT-Navigation platform for 3D guidance in interventional procedures.
Prior procedures involving CT to guide the path of needles have been long and require multiple control scans to get the best position and angle, exposing patients to more radiation.
An ergonomic universal CT solution, CT-Navigation utilizes 3D imaging to pinpoint where interventional radiologists should place stereotactic needles exactly before insertion, allowing them to preplan percutaneous procedures such as biopsies and tumor ablation, reducing time and dose in procedures and giving them continuous control for accurate outcomes.
While the system is currently only CT-based, GE HealthCare plans to expand the technology within its image-guided therapy business to scale growth. It initially will introduce the solution in medical facilities across the U.S., followed by other major markets, including Japan and China.
"It’s faster and more accurate compared to conventional 2D CT techniques, it reduces radiation exposure, and it reduces variability for ease of use," Jan Makela, president and CEO of imaging at GE HealthCare, told HCB News of CT-Navigation.
CT-Navigation includes an integrated workstation, guidance software and a disposable procedure kit. It is compatible with all CT scanners and needle sizes, from 25 gauge to 11 gauge, and works with both soft and hard tissue. GE HealthCare's CT, molecular imaging and interventional businesses will utilize the technology to further their individual precision care objectives.
The solution is FDA cleared and approved under the European Union’s Medical Devices Regulation, and is used by major health systems in both geographic areas, according to Pierre Olivier, president and CEO of IMACTIS, who says GE HealthCare’s large sales team and extensive connections with providers will scale and expand the reach of CT-Navigation.
"Our product development team also sees significant opportunities to integrate our hardware and software into GE HealthCare solutions and make the workflow of the interventional radiologists and oncologists even simpler and faster," he told HCB News.
Seen as a high opportunity growth driver in the 2022 to 2026 period, demand for interventional CT capabilities continues to grow in oncology, cardiology, urology, nephrology, gastroenterology and other areas. This has pushed companies like GE HealthCare, which is a leader in CT, with a large install base and global scale, to invest more in the interventional radiology market.
The acquisition follows GE HealthCare’s spin off on January 4 from GE as an independent company. Discussions about the spin off spanned all the way back to 2018.
The new entity says that it expects organic revenue in 2023 to range from 5% to 7%, as it witnesses robust customer demand as well as an increase in the fulfillment of older orders and improved pricing, reported Reuters.
The acquisition is not expected to affect employees, says Makela.
The deal is subject to customary closing conditions, including review by relevant French governmental authorities. GE HealthCare plans to fund the transaction with cash on hand.
Financial details were not publicly disclosed.
Prior procedures involving CT to guide the path of needles have been long and require multiple control scans to get the best position and angle, exposing patients to more radiation.
An ergonomic universal CT solution, CT-Navigation utilizes 3D imaging to pinpoint where interventional radiologists should place stereotactic needles exactly before insertion, allowing them to preplan percutaneous procedures such as biopsies and tumor ablation, reducing time and dose in procedures and giving them continuous control for accurate outcomes.
Reveal Mobi Pro now available for sale in the US
Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.
"It’s faster and more accurate compared to conventional 2D CT techniques, it reduces radiation exposure, and it reduces variability for ease of use," Jan Makela, president and CEO of imaging at GE HealthCare, told HCB News of CT-Navigation.
CT-Navigation includes an integrated workstation, guidance software and a disposable procedure kit. It is compatible with all CT scanners and needle sizes, from 25 gauge to 11 gauge, and works with both soft and hard tissue. GE HealthCare's CT, molecular imaging and interventional businesses will utilize the technology to further their individual precision care objectives.
The solution is FDA cleared and approved under the European Union’s Medical Devices Regulation, and is used by major health systems in both geographic areas, according to Pierre Olivier, president and CEO of IMACTIS, who says GE HealthCare’s large sales team and extensive connections with providers will scale and expand the reach of CT-Navigation.
"Our product development team also sees significant opportunities to integrate our hardware and software into GE HealthCare solutions and make the workflow of the interventional radiologists and oncologists even simpler and faster," he told HCB News.
Seen as a high opportunity growth driver in the 2022 to 2026 period, demand for interventional CT capabilities continues to grow in oncology, cardiology, urology, nephrology, gastroenterology and other areas. This has pushed companies like GE HealthCare, which is a leader in CT, with a large install base and global scale, to invest more in the interventional radiology market.
The acquisition follows GE HealthCare’s spin off on January 4 from GE as an independent company. Discussions about the spin off spanned all the way back to 2018.
The new entity says that it expects organic revenue in 2023 to range from 5% to 7%, as it witnesses robust customer demand as well as an increase in the fulfillment of older orders and improved pricing, reported Reuters.
The acquisition is not expected to affect employees, says Makela.
The deal is subject to customary closing conditions, including review by relevant French governmental authorities. GE HealthCare plans to fund the transaction with cash on hand.
Financial details were not publicly disclosed.
You Must Be Logged In To Post A CommentRegistroRegistrarse es Gratis y Fácil. Disfruta de los beneficios del Mercado de Equipos Médicos Nuevos y Usados líder en el mundo. ¡Regístrate ahora! |
|
